GSK's acquisition of IDRx aims to enhance its oncology portfolio by addressing a significant gap in gastrointestinal cancer treatments, particularly targeting mutations in the KIT gene.
IDRx's lead treatment, IDRX-42, is designed to tackle the mutations responsible for gastrointestinal stromal tumours (GIST), a rare cancer with no recent advances in treatment.
Tim Clackson emphasized the collaboration with GSK, expressing eagerness to advance IDRX-42, noting the stagnation of treatment advancements for GIST over the past two decades.
GSK's chief scientific officer, Tony Wood, highlighted the promise of IDRX-42's early clinical data, expressing hope to expedite its development to redefine treatment options.
Collection
[
|
...
]